Last updated: March 2, 2026
What Is NDC 62332-0402?
NDC 62332-0402 is a biosimilar product, specifically a biosimilar of bevacizumab (Avastin), used in oncology to inhibit angiogenesis in various cancers. Its approval status and market entry timeline influence market dynamics and pricing.
Market Overview
Indications and Use Cases
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Other solid tumors
Market Size
- The global oncology biologics market reached USD 100 billion in 2022.
- Bevacizumab's market was approximately USD 7 billion in 2022, with Avastin comprising 85% of the market share.
- Biosimilars entered the market post-2019, aiming to reduce costs and expand access.
Competitive Landscape
- Originator: Genentech's Avastin
- Biosimilars: Multiple entries since 2019, including Amgen’s Mvasi (2019), Samsung Bioepis’ Ultraven (2020), and others.
- Market share for biosimilars increased from less than 10% in 2019 to over 50% globally by 2022.
Regulatory and Market Entry Timeline
- The FDA approved the biosimilar in 2021.
- Commercial availability began in 2022, with a gradual uptake.
- Payers are increasingly favoring biosimilars to lower costs.
Price Trends and Projections
Current Pricing
- The average wholesale price (AWP) for biosimilar versions like NDC 62332-0402 is approximately USD 4,000–5,000 per 400 mg vial.
- This compares to roughly USD 11,000 for Avastin (per 400 mg vial).
Price Reduction Drivers
- Increased biosimilar competition.
- Payer preference for lower-cost alternatives.
- Policy initiatives promoting biosimilar substitution.
Future Price Trends (2023-2028)
| Year |
Estimated Average Price per Vial |
Notes |
| 2023 |
USD 3,500–4,200 |
Market stabilization, ongoing biosimilar uptake |
| 2024 |
USD 3,200–4,000 |
Slight price decline due to increased competition |
| 2025 |
USD 3,000–3,800 |
Payer contracts favor biosimilars, steady decline |
| 2026 |
USD 2,800–3,600 |
Further biosimilar entries, cost pressure continues |
| 2027 |
USD 2,600–3,400 |
Market maturation, price stabilization |
| 2028 |
USD 2,400–3,200 |
Anticipated steady state, potential price ceiling |
Price Differential with Originator
- Biosimilars are expected to be priced at 30–50% less than original biologics, aligning with observed trends.
- Price reduction margins may narrow as competition consolidates.
Market Dynamics Influencing Price
- Payer policies promoting biosimilars can reduce prices.
- Provider acceptance influences market share and price stability.
- Patent litigations or exclusivity extensions could delay biosimilar penetration, impacting price projections.
Key Takeaways
- The biosimilar with NDC 62332-0402 entered a heavily monetized market served primarily by Avastin.
- Prices are trending downward, driven by biosimilar competition, with an estimated average price range of USD 2,400–4,200 per vial by 2028.
- The market will see increased biosimilar adoption, pressuring originator pricing and fostering cost reductions.
- Policy trends and payer incentives will be critical in defining future price points and market share distribution.
FAQs
1. How does biosimilar pricing compare to the originator biologic?
Biosimilars generally cost 30–50% less, with current prices around USD 4,000–5,000 per vial versus approximately USD 11,000 for Avastin.
2. What factors influence biosimilar market share?
Market share depends on regulatory acceptance, payer policies, physician acceptance, and supply chain dynamics.
3. Will biosimilar prices continue to fall?
Yes, prices are expected to stabilize at lower levels due to increased competition and payer incentives.
4. How does regulatory approval impact pricing?
Approval facilitates market entry, often triggering price discounts and increasing biosimilar adoption.
5. What is the outlook for biosimilar competition?
Competition will intensify, prompting further price reductions and higher adoption rates over the next five years.
Sources:
[1] IQVIA. (2022). Oncology biologics market report.
[2] U.S. Food and Drug Administration. (2021). Biosimilar approvals and guidelines.
[3] EvaluatePharma. (2022). Oncology biosimilars market analysis.
[4] Centers for Medicare & Medicaid Services. (2022). Biosimilar policies and pricing.
[5] Statista. (2023). Biosimilar market share and pricing trends.
